Skip to main content

Table 2 Demographics and clinical characteristics of donors with LP, PSP tau pathology, GCI pathology and other types of pathology

From: Neuropathological correlates of parkinsonian disorders in a large Dutch autopsy series

 

LP

PSP tau pathology

GCI pathology

Other types of pathology

N

162

45

28

58

Sex M, n (%)

102 (63%)

28 (62%)

10 (36%)**

36 (62%)

Age at onset y, mean ± SD (range)

<  50 / 50–75 / >  75 y, n (%)

62 ± 11 (32–88)

26/117/19 (16/72/12%)

66 ± 7 (51–84)**

0/40/5 (0/89/11%)

59 ± 9 (45–81)

3/23/2 (11/82/7%)

64 ± 12 (34–84)

7/43/8 (12/74/14%)

Age at death y, mean ± SD (range)

77 ± 8 (56–96)

74 ± 8 (57–90)

66 ± 9 (52–84)***

76 ± 11 (42–98)

Disease duration y, mean ± SD (range)

15 ± 7 (2–42)

8 ± 4 (3–23)***

7 ± 3 (3–16)***

11 ± 9 (0.5–41)**

Dementia, n (%)

89 (55%)

12 (27%)***

2 (7%)***

30 (52%)

Duration of dementia y, mean ± SD (range)

4 ± 3 (0–12)

2 ± 2 (0–6)**

1 ± 1 (0–1)

3 ± 2 (0–10)

Visual hallucinations, n/N (%)

93/122 (76%)

10/13 (77%)

5/7 (71%)

9/13 (69%)

Rest tremor, n/N (%)

112/134 (84%)

11/30 (37%)***

16/24 (67%)

29/37 (78%)

Clear response to dopaminergic therapy, n/N (%)

106/126 (84%)

6/26 (23%)***

11/24 (46%)***

10/26 (39%)***

Positive family history of parkinsonism, n/N (%)

31/80 (39%)

7/28 (25%)

3/17 (18%)

8/29 (28%)

APOE ε4 alleles, n/N (%)

 0

67/101 (66%)

23/39 (59%)

12/23 (52%)

33/43 (77%)

 1

31/101 (31%)

15/39 (39%)

9/23 (39%)

9/43 (21%)

 2

3/101 (3%)

1/39 (3%)

2/23 (9%)

1/43 (2%)

  1. Groups are compared using analysis of covariance for continuous variables and chi-square tests for categorical variables. When significant, the LP group was compared to the other pathology groups using post-hoc tests for continuous variable and chi-square tests for categorical variables.* p < 0.05; ** p < 0.01; *** p < 0.001